一、独立董事基本情况 公司董事会由 9 名董事组成，其中包括 3 名独立董事。独立董事人数为董事 会人数的三分之一以上，且为会计、法律、公司所从事行业等领域的专业人士， 符合相关法律法规中关于上市公司独立董事人数比例和专业配置的要求，保证了 董事会决策的独立性。公司第四届董事会独立董事为谢树志先生、刘林森女士和 杨渊先生。 （一）独立董事个人基本情况 谢树志，男，1965 年 7 月出生，中国国籍，无境外永久居留权。上海财经 大学财政学系经济学学士、南京大学会计学系管理学硕士，中国注册会计师、注 册资产评估师、国际注册内部审计师、高级会计师。现任公司独立董事，永悦科 技股份有限公司、丹化化工科技股份有限公司独立董事，安徽省港航集团有限公 司董事。 （二）培训情况说明 2024 年，本人积极参加培训，持续提升履职所需的专业知识和能力。2024 年 11 月，本人参加了上海上市公司协会举办的"2024 年上市公司董事监事高管 培训班"并完成全部课程的培训，培训结束收到相关单位颁发的培训证书。2024 年 12 月，本人参加上海证券交易所推出的"上市公司独立董事反舞弊履职要点 及建议"专题课程的培训，进一步提升独立 ...

上海荣泰健康科技股份有限公司 2025 年员工持股计划管理办法 转债简称：荣泰转债 转债代码：113606 证券简称：荣泰健康 证券代码：603579 上海荣泰健康科技股份有限公司 2025 年员工持股计划 管理办法 上海荣泰健康科技股份有限公司 二零二五年四月 1 上海荣泰健康科技股份有限公司 2025 年员工持股计划管理办法 总则 为了进一步建立、健全公司长效激励机制，吸引和留住优秀人才，充分调动 本公司核心管理人员的积极性，有效的将股东利益、公司利益和核心团队利益结 合在一起，使各方共同关注公司的长远发展，促进公司战略目标的实现，在充分 保障股东利益的前提下，按照收益与贡献对等的原则，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《关于上市公司实施员工持股计划试点的指导意见》（以下简称"《指导意见》"）、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》（以下简称"《自 律监管指引第 1 号》"）等有关法律、法规和规范性文件以及《上海荣泰健康科技 股份有限公司章程》（以下简称"《公司章程》"）的规定，制订了《上海荣泰健康 科技 ...

上海荣泰健康科技股份有限公司 2024 年度独立董事述职报告 本人刘林森，作为上海荣泰健康科技股份有限公司（以下简称"公司"）的 独立董事，于 2022 年 10 月 18 日召开的公司 2022 年第二次临时股东大会上被 选举为公司第四届董事会独立董事。在 2024 年度严格按照《中华人民共和国公 司法》《上市公司独立董事管理办法》等相关法律法规的规定及《上海荣泰健康 科技股份有限公司章程》《上海荣泰健康科技股份有限公司独立董事工作制度》 的规定，认真履行职责，积极出席公司相关会议，充分发挥独立董事的独立作 用，切实维护公司和全体股东利益。现将 2024 年度任职期间本人的履职情况报 告如下： 一、独立董事基本情况 刘林森，女，1977 年 3 月出生，中国国籍，无境外永久居留权，法学硕士， 执业律师。历任北京市齐致律师事务所实习律师、北京市金诚同达律师事务所任 律师。现任北京大成律师事务所高级合伙人、公司独立董事。 公司董事会由 9 名董事组成，其中包括 3 名独立董事。独立董事人数为董事 会人数的三分之一以上，且为会计、法律、公司所从事行业等领域的专业人士， 符合相关法律法规中关于上市公司独立董事人数比 ...

上海荣泰健康科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 目 录 | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、上海荣泰健康科技股份有限公司关于 2024 年度募集资金 | | | 存放与使用情况的专项报告 | 4-11 | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.z ...

万和证券股份有限公司关于 上海荣泰健康科技股份有限公司 2024 年度募集资金 存放与实际使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号-上市 公司募集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第1号—规范运作》和《上海证券交易所上市 公司自律监管指引第 11 号-持续督导》等有关法律法规的要求,万和证券股份 有限公司(以下简称"万和证券"或"保荐机构")就上海荣泰健康科技股份有限公 司（简称"荣泰健康"、"上市公司"、"公司"）2024 年度募集资金存放与使用情况 进行了核查,情况如下: 一、募集资金基本情况 (一) 募集资金金额及到位情况 经中国证券监督管理委员会《关于核准上海荣泰健康科技股份有限公司公开 发行可转换公司债券的批复》(证监许可[2020]2139 号)核准,公司公开发行 600 万张 A 股可转换公司债券(每张面值 100 元人民币),募集资金总额为人民 币 60.000.00 万元。公司扣除剩余部分应支付的承销及保荐费用后，实际收到可 转换公司债券认购资金人民币 59,730.00 万元。该款项 ...

万和证券股份有限公司关于 上海荣泰健康科技股份有限公司 2024 年度募集资金 存放与实际使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号-上市 公司募集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第1号—规范运作》和《上海证券交易所上市 公司自律监管指引第 11 号-持续督导》等有关法律法规的要求,万和证券股份 有限公司(以下简称"万和证券"或"保荐机构")就上海荣泰健康科技股份有限公 司（简称"荣泰健康"、"上市公司"、"公司"）2024 年度募集资金存放与使用情况 进行了核查,情况如下: 一、募集资金基本情况 (一) 募集资金金额及到位情况 经中国证券监督管理委员会《关于核准上海荣泰健康科技股份有限公司公开 发行可转换公司债券的批复》(证监许可[2020]2139 号)核准,公司公开发行 600 万张 A 股可转换公司债券(每张面值 100 元人民币),募集资金总额为人民 币 60.000.00 万元。公司扣除剩余部分应支付的承销及保荐费用后，实际收到可 转换公司债券认购资金人民币 59,730.00 万元。该款项 ...

上海荣泰健康科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 4-11 年度募集资金存放与使用情况鉴证报告 中汇会鉴[2025]4432号 上海荣泰健康科技股份有限公司全体股东: 我们签证了后附的上海荣泰健康科技股份有限公司(以下简称荣泰健康公司) 管理层编制的《关于2024年度募集资金存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 目 录 | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、上海荣泰健康科技股份有限公司关于 2024 年度募集资金 | | | 存放与使用情况的专项报告 | 4-11 | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 394,971,319.77, a decrease of 1.41% compared to CNY 400,613,890.42 in the same period last year[4]. - Net profit attributable to shareholders decreased by 29.97% to CNY 43,938,868.26 from CNY 62,741,790.01 year-on-year[4]. - The basic earnings per share (EPS) fell by 32.43% to CNY 0.25, down from CNY 0.37 in the previous year[4]. - Total revenue for Q1 2025 was CNY 394,971,319.77, a decrease of 1.6% from CNY 400,613,890.42 in Q1 2024[21]. - Net profit for Q1 2025 was CNY 43,998,236.11, down 30.0% from CNY 62,847,346.26 in Q1 2024[22]. - Earnings per share (EPS) for Q1 2025 was CNY 0.25, compared to CNY 0.37 in Q1 2024[23]. - The company reported a total comprehensive income of CNY 68,111,591.28 for Q1 2025, compared to CNY 60,953,288.76 in Q1 2024[23]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,354,188,533.65, a decline of 10.36% from CNY 3,742,040,010.16 at the end of the previous year[5]. - Current assets totaled RMB 1,897,601,555.66, down from RMB 2,177,791,254.00[16]. - Total liabilities amounted to CNY 1,278,059,295.89, a decrease from CNY 1,726,421,575.63 year-over-year[18]. - Total equity attributable to shareholders increased to CNY 2,074,584,865.54 from CNY 2,014,115,666.39 in the previous year[18]. Cash Flow - The net cash flow from operating activities improved to CNY -34,477,414.01, compared to CNY -150,370,360.33 in the same period last year, indicating a significant improvement[4]. - Cash inflow from operating activities totaled CNY 465,077,173.97, an increase from CNY 434,769,564.08 in Q1 2024[25]. - The net cash flow from investment activities was $452.73 million, compared to -$88.45 million in the prior period[26]. - Cash inflow from financing activities was $45.66 million, down from $265.55 million in the previous year[26]. - The ending cash and cash equivalents balance was $603.67 million, compared to $1.31 billion at the end of the previous period[26]. Shareholder Information - The top shareholder, Lin Qi, holds 25.58% of the shares, with a total of 45,370,299 shares[10]. - The company has identified several shareholders with significant holdings, including Lin Qi with 45,370,299 shares[11]. - The company held 2,303,200 shares in its repurchase account, representing 1.30% of total shares[12]. Legal Matters - The company was ordered to pay RMB 5.1 million in damages related to a patent infringement lawsuit[13]. - The company is currently involved in a legal dispute regarding patent rights, with an uncertain outcome pending[14]. Operational Costs and Expenses - Total operating costs increased to CNY 359,966,503.86, up 8.6% from CNY 331,559,198.75 in the same period last year[21]. - Research and development expenses for Q1 2025 were CNY 21,310,597.42, up from CNY 20,142,315.83 in Q1 2024[22]. Other Financial Metrics - The weighted average return on equity (ROE) was 2.16%, down from 3.14% in the previous year, reflecting a decrease of 0.98 percentage points[5]. - Non-recurring gains and losses totaled CNY 11,472,634.84, with government subsidies contributing CNY 2,615,365.88[7]. - The company’s deferred income tax liabilities rose to CNY 15,399,670.99 from CNY 9,196,242.74 year-over-year[18].

Financial Performance - The company's operating revenue for 2024 was CNY 1,596,868,348.54, a decrease of 13.92% compared to CNY 1,855,029,390.81 in 2023[23] - The net profit attributable to shareholders for 2024 was CNY 191,945,865.16, down 5.31% from CNY 202,706,851.03 in the previous year[23] - The net profit after deducting non-recurring gains and losses was CNY 163,207,478.98, a decrease of 12.47% from CNY 186,468,334.48 in 2023[23] - Cash flow from operating activities for 2024 was CNY 168,142,471.76, down 51.16% from CNY 344,294,659.84 in 2023[23] - The total assets at the end of 2024 were CNY 3,742,040,010.16, an increase of 10.55% compared to CNY 3,384,898,669.64 at the end of 2023[23] - The net assets attributable to shareholders increased to CNY 2,014,115,666.39, a rise of 2.30% from CNY 1,968,889,002.67 in 2023[23] - Basic earnings per share decreased by 5.13% to 1.11 yuan, while diluted earnings per share fell by 17.09% to 0.97 yuan[24] - The total profit amounted to ¥209,994,119.33, down 8.77% year-on-year, while the net profit attributable to the parent company was ¥191,945,865.16, a decline of 5.31%[75] - The operating cash flow net amount was ¥168,142,471.76, reflecting a significant decline of 51.16% year-on-year[77] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.50 per 10 shares (including tax) based on the total share capital on the dividend distribution date[6] - The company will also distribute an additional cash dividend of CNY 3.00 per 10 shares in the mid-2024, totaling CNY 6.50 per 10 shares for the entire year[6] - The total cash dividend amount for the last three accounting years was RMB 316,294,821.95[171] - The cash dividend ratio for the last three accounting years was 218.30%[172] - The company distributed a total cash dividend of RMB 113,806,248.45, which represents 59.29% of the net profit attributable to ordinary shareholders[169] - The company has a cash dividend policy that complies with its articles of association and shareholder resolutions[167] Market and Sales Performance - The company achieved operating revenue of 1.597 billion yuan in 2024, a decrease of 13.92% compared to the previous year[34] - The company experienced a decline in customer orders due to global economic downturns, with revenue in the Korean market decreasing year-on-year, while Amazon's cross-border e-commerce business grew by 60%[37] - The company added 23 specialty stores in 2024, bringing the total to 103 operational specialty stores[35] - The company’s sales growth was driven by an increase in sales channels and improved single-store output, particularly in second and third-tier cities[72] - The massage chair market share is expected to increase significantly due to rising consumer income and health awareness[120] Research and Development - The company invested CNY 80.1 million in R&D, accounting for 5.02% of revenue, and completed 22 R&D projects, resulting in 31 new invention patents and 34 utility model patents[39] - Key breakthroughs in flexible rail design improved cost control and production efficiency, while innovations in calf massage technology enhanced user experience[40] - The company emphasizes technological innovation in product development, focusing on AI, VR, and health data collection to enhance user engagement[70] - The company will increase R&D investment to maintain technological leadership and enhance brand influence through effective marketing strategies[134] Strategic Initiatives - The company is focusing on enhancing brand influence and expanding its market presence through channel reforms and new product promotions[35] - The company is actively seeking mergers and acquisitions in the health industry, particularly targeting companies with AI technology capabilities[127] - The company aims to establish overseas production bases, with a factory in Thailand expected to be operational by the end of 2025[123] - The company is adapting to product trends towards smart, portable, and multifunctional designs, integrating AI and IoT technologies into its offerings[50] Corporate Governance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring effective operation and accountability[136] - The board of directors has set up specialized committees, including a strategy committee and an audit committee, to oversee various aspects of corporate governance[137] - The company has approved several key proposals at its shareholder meetings, including the 2023 annual report and the 2024 employee stock ownership plan[140] Environmental and Social Responsibility - The company achieved a reduction of 2,470.9 tons in carbon emissions through various measures, including the construction of a 1.7MWp distributed rooftop photovoltaic project, which generated approximately 177.4 million kWh of electricity[180] - The company has engaged in various environmental protection initiatives, including the use of clean energy and the promotion of sustainable practices[180] - The company has been recognized as an advanced unit for voluntary blood donation in both Zhu Jia Jiao Town and Shanghai City for several consecutive years[192] - The company has established multiple community service bases, achieving a satisfaction rate of over 95%[191] Risk Management - The company has identified raw material price fluctuations as a risk, as over 80% of its cost structure is dependent on raw materials[129] - The company faces risks from fluctuations in the RMB exchange rate, as its export business is primarily settled in USD, which can impact operating performance[132] - To mitigate exchange rate risks, the company plans to use RMB for contract settlements and employ hedging tools for risk management[133] Employee Engagement and Welfare - The company has arranged for 883 employee health check-ups in 2024[188] - The company has organized over 500 participants for various sports and health activities throughout the year[188] - The company has signed special collective contracts to protect the rights and interests of female employees[188] - The company has established a mechanism for regular safety training and emergency drills for employees[188]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-024 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于开展远期结售汇业务和外汇衍生产品业务的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 4 月 23 日，上海荣泰健康科技股份有限公司（以下简称"公司"） 召开第四届董事会第二十一次会议、第四届监事会第十六次会议，审议通过了《关 于公司 2025 年开展远期结售汇业务和外汇衍生产品业务的议案》及《关于开展 交易目的：由于公司国际业务的外汇收付金额较大，外汇汇率/利率波动对 公司经营成果可能产生较大影响。为减少外汇汇率/利率波动带来的风险， 公司拟开展远期结售汇、外汇期权产品等业务，以降低外汇汇率/利率波动 带来的风险； 交易品种：外汇汇率，包括但不限于美元、欧元、港币、韩元等币种； 交易工具：远期结售汇业务、外汇衍生产品业务； 交易场所：具有合法经营资格的金融机构； 交易金 ...